

Day 1: Thursday 09 December 2021

Time	Subject	Presenter(s)
07:15	Log on to Zoom	
07:30	Welcome	Peter Billingsley
07:35	Introduction to the Meeting: what we want to accomplish	Stephen Hoffman
07:45	In Memory of Prof. Malcolm Molyneux	Thomas Richie
07:50	Opening remarks	Peter Kreamsner, Alassane Dicko
<b>Directions for PfSPZ vaccines</b>		
08:00	Global-WHO perspective on malaria vaccines	Pedro Alonso
08:10	Sanaria progress and strategies	Stephen Hoffman
08:30	Regulatory opinions: EMA and FDA	Anusha Gunasekera
08:45	Discussion	<b>Moderators: Marcel Tanner, Fred Binka, Graham Brown</b>
<b>PfSPZ Vaccine - travelers, pregnancy, and children</b>		
08:55	Introduction: Pathway to a vaccine for travelers	Preston Church
09:00	MAVACHE: Germany (CHMI) - the starting point	Benjamin Mordmüller
09:05	Warfighter 3: US (CHMI)	Jim Kublin
09:13	TravSPZV1 (and U44): Europe and US (CHMI)	Thomas Richie/Peter Kreamsner/Kirsten Lyke/Patrick Duffy
09:23	IDSPZV1 (field trial in soldiers deployed to Papua): Indonesia	Erni Nelwan/Kevin Baird
09:31	PfSPZ Challenge (MAL31): a Pf parasite from Malawi	Kim Lee Sim/Ashley Vaughan
09:37	PvSPZ Challenge (Chesson)	Sumana Chakravarty
09:43	Discussion	<b>Moderators: Martin Grobusch, Preston Church</b>
09:58	Introduction: Pathway to a vaccine to prevent malaria in pregnancy	Thomas Richie
10:03	MLSPZV4: 2 years of vaccine efficacy in Malian women, many of whom became pregnant	Halimatou Diawara
10:13	Pivoting to a vaccine for non-pregnant women who may become pregnant	Patrick Duffy/Alassane Dicko
10:21	MLSPZV6: Immunization of pregnant women in third and second trimesters	Sara Healy
10:26	Discussion	<b>Moderators: Rose Leke, Clara Menendez</b>
<b>Coffee</b>		
10:41		
10:51	Introduction: Pathway to a vaccine for children	Thomas Richie
10:56	MLSPZV5: Seasonal malaria prevention in Malian children	Issaka Sagara
11:04	EGSPZV4: Protection against perennial malaria transmission in children in Equatorial Guinea	Said Jongo
11:12	The requirement for presumptive treatment in field trials	Peter Billingsley/Aye Diallo Sousa/Halimatou Diawara
11:20	Discussion	<b>Moderators: Salim Abdulla, Brian Greenwood</b>
11:35	Wrap up comments: PfSPZ Vaccine - travelers, pregnancy and children	Stephen Hoffman
<b>The funders' perspective</b>		
11:40	Introduction and overview	Stephen Hoffman
11:45	The EU Malaria Fund and its successors	Holm Keller
11:50	NIAID-NIH	Lee Hall
11:55	Government of Equatorial Guinea and energy companies	Mitoha Ondo'o Ayekaba, Bonifacio Manguire
12:00	EDCTP	Pauline Beattie
12:05	Prince Ned Nwoko Malaria Eradication Project	Prince Ned Nwoko/Anyaduba Chuks
12:10	Discussion	<b>Moderators: Annie Mo, Holm Keller</b>
12:20	Open Discussion	Pete Billingsley
12:30	Closing remarks	Stephen Hoffman



# International PfSPZ Consortium Meeting

Day 2: Friday 10 December 2020

Time	Subject	Presenter
07:15	Log on to Zoom	
07:30	Introduction to the day	Stephen Hoffman
	<b>Reducing cost of goods and increasing efficiency of manufacture by increasing potency: from PfSPZ-CVac to PfSPZ-LARC</b>	
07:35	Overview of PfSPZ-CVac and PfSPZ-LARC clinical development plan	Thomas Richie
07:40	PfSPZ-CVac (PYR) - field trial in adults in Mali (completed)	Mahamadoun Hamady Assadou Maiga, David Cook
07:48	IDSPZV1 (field trial of PfSPZ-CVac [CQ] in soldiers deployed to Papua): Indonesia (planned)	Erni Nelwan, Kevin Baird
07:53	PfSPZ-CVac (pyronaridine) (SPICY) (CHMI): Germany (planned)	Andrea Kreidenweiss
07:59	PfSPZ-CVac in African children: Phase 2 clinical trial (planned)	Sodiomon Sirima
08:04	Development and GMP manufacture of late-arresting, replication competent (LARC), genetically attenuated	Ashley Vaughan/Kim Lee Sim
08:09	Update on progress with the clinical trial with GA2 (PfΔmei2), a genetically attenuated parasite that arrests late in the liver	Blandine Franke-Fayard
08:14	Plans and timeline for new phase 1 facility: first product PfSPZ-LARC2	Kim Lee Sim
08:26	PfSPZ-LARC clinical trial (CHMI): Germany	Peter Krensner
08:31	PfSPZ-LARC clinical trial (CHMI): US	Sean Murphy
08:36	Discussion	<b>Moderators: Meta Roestenberg, Michael Good</b>
	<b>Reducing cost of goods and increasing efficiency of manufacture by eliminating mosquitoes from manufacturing: In vitro-produced PfSPZ (iPfSPZ)</b>	
08:51	Overview	Stephen Hoffman
08:56	Progress toward scaling up <i>in vitro</i> production of PfSPZ in bioreactors	Abraham Eappen
09:06	The transcriptome by RNA-seq of <i>in vitro</i> -produced PfSPZ vs mosquito-produced PfSPZ	Gigliola Zanghi
09:16	Challenges to substituting in vitro-produced PfSPZ for mosquito-produced PfSPZ in PfSPZ vaccines	Stephen Hoffman
09:26	Cell biology approaches to improve the quality/quantity of iPfSPZ	Abraham Eappen/Ahmed Aly
09:36	Discussion	<b>Moderators: Photini Sinnis, Sandra March</b>
	<b>Improving vaccine efficacy and efficiency</b>	
09:51	Improving vaccine efficacy and efficiency through use of a glycolipid adjuvant	Sumana Chakravarty
09:56	Improving vaccine efficacy and efficiency by the prime and trap approach	Felicia Watson/Sean Murphy
10:04	Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasites (U01)	Kim Lee Sim, Ashley Vaughan
10:09	The potential for combining a PfSPZ vaccine with Pfs230 or expressing Pfs230 by PfSPZ	Patrick Duffy
10:14	Update on new grant to further characterize and develop P. berghei sporozoites expressing PfCSP	Miguel Prudencio
10:19	Discussion	<b>Moderators: Kirsten Lyke, Kojo Koram</b>
10:29	Coffee	
	<b>Monoclonal antibodies as immunoprophylaxis: 30 min</b>	
10:39	General overview of progress and plans	Stephen Hoffman
	<b>Model systems</b>	
10:49	Model systems: NHP Models to Assess Immunological Mechanisms and Antigenic Targets of SPZ Vaccines (U01)	Sumana Chakravarty
10:54	Model systems: Aotus lemurinus grieseimembra for assessing PfSPZ-induced liver stage infections	Patrick Duffy
11:01	Model systems: Pig-tailed macaques for assessing Pk vaccines and challenge	Melanie Shears
11:06	Generation and characterization of transgenic berghei/yoelii lines expressing antigens of P. falciparum and P. vivax	Blandine Frank-Fayarde
	<b>Immunology</b>	
11:13	Innate immune activation at the pre-immunization baseline is associated with reduced protective efficacy of the PfSPZ Vaccine in Kenyan infants	Tuan Tran
11:20	Immunology: Updates on Vd2 gd T cells and RNA-seq in studies in Mali and US	Irfan Zaidi, John Tsang
11:30	Systems serology data from PfSPZ Vaccine clinical trial	Galit Alter
11:30	Antibody feedback shapes B cell responses to the PfSPZ vaccine	Ian Cockburn
11:37	IgA antibodies to PfSPZ: Are they important?	Johsua Tan
11:43	IgA antibodies to PfSPZ: Are they important?	Andrea Berry
11:49	PfMSP5: Is this an important target of PfSPZ-induced protective immunity?	Joe Campo/Natasha KC
11:55	PfMSP5: Is this an important target of PfSPZ-induced protective immunity?	Anne Thumbo/Rolf Fendel
12:01	Immunology: Update from IMRAS	Ken Stuart
12:07	Discussion	<b>Moderators: Galit Alter, John Tsang</b>
	<b>Close out session</b>	
12:22	Open discussion	Pete Billingsley
12:37	Final remarks	Stephen Hoffman